Cancer trials aimed at 'surrogate' targets miss bigger mark — study
Find a random person on the street and ask them what a cancer drug should do. What are the odds they don’t say “it should help patients live healthier and longer”?
A confluence of forces have pushed clinical trials away from that seemingly central question, with developers and patient groups betting on the promise that aiming at more subtle measures can help bring needed therapies to market faster. But a new study from the British Medical Journal suggests the conventional wisdom may be right and that trend, among others, have led cancer drugs to hit the market based off studies that have a high risk of bias.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.